$32 million additional capital raised, supported by all major existing investors and new investor Kreos Capital Ongoing Phase 1b trial of CB307 enhanced with additional pembrolizumab combination ...
Crescendo Health’s real-world data platform creates partnerships between researchers and patients to gain greater longitudinal insights into health outcomes from clinical research. Company also raises ...